Takashi Owa
Corporate Officer/Principal en EISAI CO., LTD. .
Perfil
Takashi Owa is currently the Chief Executive Officer & Director at H3 Biomedicine, Inc. He also holds the position of Chief Discovery Officer, Head-Japan & Asia Medical at Eisai Co., Ltd.
Cargos activos de Takashi Owa
| Empresas | Cargo | Inicio |
|---|---|---|
| EISAI CO., LTD. | Corporate Officer/Principal | 01/04/1991 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Director Ejecutivo | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Empresas privadas | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Bolsa de valores
- Insiders
- Takashi Owa
